论文部分内容阅读
目的:对76例肺癌患者经过2个周期NP或GP或EP方案化疗后,检测第一次和第三次化疗前血清肿瘤标记物CEA、CA125、NSE水平的变化,并根据影像学结果的化疗前后改变来进行对比分析。方法:采用蛋白芯片法测定CEA、CA125、NSE。结果:2周期化疗后,CEA、CA125、NSE水平均较化疗前下降,其中CEA、CA125对于化疗前后疗效评定有临床意义(P<0.05)。而NSE的下降没有统计学差异。结论:通过监测CEA、CA125化疗前后水平变化有助于肺癌化疗疗效的评定。
OBJECTIVE: To detect the change of serum tumor markers CEA, CA125 and NSE before and after the first and third chemotherapy in 76 patients with lung cancer after two cycles of NP or GP or EP chemotherapy. According to the imaging results of chemotherapy Before and after changes to carry out comparative analysis. Methods: CEA, CA125 and NSE were determined by protein chip method. Results: After 2 cycles of chemotherapy, the levels of CEA, CA125 and NSE decreased compared with that before chemotherapy. CEA and CA125 had clinical significance before and after the chemotherapy (P <0.05). There was no statistical difference in the decline of NSE. Conclusion: The changes of CEA and CA125 levels before and after chemotherapy are helpful to evaluate the efficacy of chemotherapy for lung cancer.